This is a Validated Antibody Database (VAD) review about mouse Vav1, based on 5 published articles (read how Labome selects the articles), using Vav1 antibody in all methods. It is aimed to help Labome visitors find the most suited Vav1 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
Vav1 synonym: Vav; vav-T

Santa Cruz Biotechnology
mouse monoclonal (D-7)
  • western blot; mouse; loading ...; fig 6c
Santa Cruz Biotechnology Vav1 antibody (Santa Cruz, sc8039) was used in western blot on mouse samples (fig 6c). J Biomed Sci (2021) ncbi
mouse monoclonal (D-7)
  • western blot; human; 1:1000; fig 3
Santa Cruz Biotechnology Vav1 antibody (Santa Cruz, sc-8039) was used in western blot on human samples at 1:1000 (fig 3). elife (2016) ncbi
Abcam
domestic rabbit polyclonal
  • western blot; mouse; loading ...; fig 6b
Abcam Vav1 antibody (Abcam, ab47282) was used in western blot on mouse samples (fig 6b). Mol Biol Cell (2017) ncbi
domestic rabbit polyclonal
  • western blot; human; loading ...; fig 7a
In order to investigate NF-KB signaling in natural killer cells, Abcam Vav1 antibody (Abcam, ab47282) was used in western blot on human samples (fig 7a). Nat Commun (2016) ncbi
Cell Signaling Technology
domestic rabbit polyclonal
  • western blot; mouse; loading ...; fig 1a
Cell Signaling Technology Vav1 antibody (Cell signaling technology, 2502) was used in western blot on mouse samples (fig 1a). Cell Rep (2019) ncbi
domestic rabbit polyclonal
  • western blot; mouse; loading ...; fig 6b
Cell Signaling Technology Vav1 antibody (Cell Signaling, 2502) was used in western blot on mouse samples (fig 6b). Mol Biol Cell (2017) ncbi
Articles Reviewed
  1. Hsu Y, Hsu F, Chiang M, Tsai D, Li F, Angata T, et al. Siglec-E retards atherosclerosis by inhibiting CD36-mediated foam cell formation. J Biomed Sci. 2021;28:5 pubmed publisher
  2. Celis Gutierrez J, Blattmann P, Zhai Y, Jarmuzynski N, Ruminski K, Gregoire C, et al. Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy. Cell Rep. 2019;27:3315-3330.e7 pubmed publisher
  3. Schwartz S, Cleyrat C, Olah M, Relich P, Phillips G, Hlavacek W, et al. Differential mast cell outcomes are sensitive to FcεRI-Syk binding kinetics. Mol Biol Cell. 2017;28:3397-3414 pubmed publisher
  4. Kwon H, Choi G, Ryu S, Kwon S, Kim S, Booth C, et al. Stepwise phosphorylation of p65 promotes NF-?B activation and NK cell responses during target cell recognition. Nat Commun. 2016;7:11686 pubmed publisher
  5. Zhang C, Liu J, Zhao Y, Yue X, Zhu Y, Wang X, et al. Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates p53 function in suppressing metastasis. elife. 2016;5:e10727 pubmed publisher